General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Statements of Changes in Stockholders' Equity

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Common Stock Dividend Payable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 504 $ 4,231,746 $ (3,859,087) $ 373,163
Balance, shares at Dec. 31, 2017 5,039,033          
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 298,615 common stock of Processa held by Promet 8,000,000 8,000,000
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants $ 17 2,312,592 2,312,609
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, shares 172,327          
Issuance of common stock units for cash, net of costs of $308,830 $ 20 2,874,667 2,874,687
Issuance of common stock units for cash, net of costs of $308,830, shares 200,369          
Issuance of common stock units for a future research funding commitment, net of costs of $168,457 $ 11 1,631,532 (1,800,000) (168,457)
Issuance of common stock units for a future research funding commitment, net of costs of $168,457, shares 113,280          
Stock-based compensation 74,063 74,063
Net loss (3,765,047) (3,765,047)
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Stock-based compensation 58,559   58,559
Payments made directly by investor for clinical trial costs 115,000   115,000
Net loss   (750,832) (750,832)
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,009          
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Net loss           (1,719,910)
Balance at Jun. 30, 2019 $ 552 19,249,635 (1,404,073)   (9,344,044) 8,502,070
Balance, shares at Jun. 30, 2019 5,525,009          
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants $ 2 258,928 258,930
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, shares 18,107          
Stock-based compensation 510,478 510,478
Payments made directly by investor for clinical trial costs 900,000 900,000
Pledged shares of common stock forfeited upon revised research funding commitment $ (5) (899,995) 900,000
Pledged shares of common stock forfeited upon revised research funding commitment, shares (56,640)          
Deemed stock dividend due to full ratchet anti-dilution adjustment (3) 3
Net loss (3,357,876) (3,357,876)
Balance at Dec. 31, 2019 $ 549 18,994,008 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476          
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,009          
Stock-based compensation 66,476   66,476
Payments made directly by investor for clinical trial costs 280,927   280,927
Net loss   (969,078) (969,078)
Balance at Jun. 30, 2019 $ 552 19,249,635 (1,404,073)   (9,344,044) 8,502,070
Balance, shares at Jun. 30, 2019 5,525,009          
Balance at Dec. 31, 2019 $ 549 18,994,008 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476          
Stock-based compensation 98,663   98,663
Transaction costs related to anticipated 2020 offering (2,806)   (2,806)
Net loss   (874,336) (874,336)
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,476          
Balance at Dec. 31, 2019 $ 549 18,994,008 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476          
Net loss           (1,607,750)
Balance at Jun. 30, 2020 $ 552 19,182,228   (12,589,760) 6,593,020
Balance, shares at Jun. 30, 2020 5,515,447          
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,476          
Stock-based compensation 93,869   93,869
Transaction costs related to anticipated 2020 offering (1,506)   (1,506)
Stock dividend distributed due to full-ratchet anti-dilution adjustment $ 3   (3)
Stock dividend distributed due to full-ratchet anti-dilution adjustment, shares 28,971          
Net loss   (733,414) (733,414)
Balance at Jun. 30, 2020 $ 552 $ 19,182,228   $ (12,589,760) $ 6,593,020
Balance, shares at Jun. 30, 2020 5,515,447